NCT07099885 Simple Urine Composition-based Personalized Algorithm for Effective Congestion Relief in Decompensated Heart Failure
| NCT ID | NCT07099885 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wroclaw Medical University |
| Condition | Acute Heart Failure (AHF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-08-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the effectiveness of loop diuretic adaptative algorithm that is based on machine learning, urine output prediction tool, in decongestion of acute heart failure patients. A total of 90 patients will be enrolled in the study. Of these, 45 will be assigned to the algorithm-based intervention group, while the remaining 45 will serve as the control group. In the control group, all decisions regarding diuretic therapy will be made solely by the attending physician, without the use of the algorithm. Patients will receive intravenous furosemide, with the initial dose determined by the attending physician. Two hours after administration of the diuretic, a spot urine sample will be collected to measure sodium and creatinine concentrations. Based on these values, the 6-hour urine output will be estimated using the machine learning, urine output prediction tool (http://diuresis.umw.edu.pl). This estimate will guide the diuretic therapy plan for the first 24 hours of hospitalization. On the second day, the procedure will be repeated using the same methodology.
Eligibility Criteria
Inclusion Criteria: * Adult patients over 18 years of age who provide informed consent * Ability to enroll in the study within the first 24 hours of hospitalization * Primary reason for hospitalization is acute heart failure with signs of congestion (at least moderate lower extremity edema) * NT-proBNP \> 1500 pg/ml * Anticipated need for diuretic therapy for at least 48 hours from the time of study enrollment Exclusion Criteria: * End-stage kidney disease requiring renal replacement therapy * Hemodynamic instability requiring inotropic support * Active infection requiring intravenous antibiotic therapy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07099885 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Heart Failure (AHF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07099885 currently recruiting?
Yes, NCT07099885 is actively recruiting participants. Contact the research team at jan.biegus@umw.edu.pl for enrollment information.
Where is the NCT07099885 trial being conducted?
This trial is being conducted at Wroclaw, Poland, Wroclaw, Poland.
Who is sponsoring the NCT07099885 clinical trial?
NCT07099885 is sponsored by Wroclaw Medical University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.